Back to All Events

Cardiovascular and Renal Drugs Advisory Committee (CRDAC)

The US FDA has scheduled a Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting for Wednesday, April 15, 2015 to discuss new drug application New Drug Application 204958, cangrelor injection, submitted by The Medicines Company, for the proposed indication of reduction of thrombotic cardiovascular events including stent thrombosis (events related to blood clots in a stent, a device inserted to keep the artery open) in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.